SCHEMBL260187

SCHEMBL260187

Clc1cccc2nccn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.53
ROCK1 Q13464 2/20 0.53
CHEK1 O14757 2/20 0.53
DYRK1B Q9Y463 2/20 0.53
MAP4K4 O95819 1/20 0.53
CSF1R P07333 1/20 0.53
PRKACA P17612 1/20 0.53
KDR P35968 1/20 0.53
MAP2K1 Q02750 1/20 0.53
ACVR1 Q04771 1/20 0.53
MAP4K2 Q12851 1/20 0.53
DYRK1A Q13627 1/20 0.53
AURKB Q96GD4 1/20 0.53
LIMK1 P53667 2/20 0.47
CLK4 Q9HAZ1 2/20 0.47
FLT1 P17948 1/20 0.47
CDK9 P50750 1/20 0.47
ADORA3 P0DMS8 1/20 0.42
LTK P29376 1/20 0.38
GRK5 P34947 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL9524427 0.98 CDK8 (0.52) CDK8ROCK1CHEK1DYRK1BMAP4K4
Hydrochloric Acid SCHEMBL7834151 0.98 CDK8 (0.52) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL334306 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL22836801 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL7896883 0.74 CDK8 (0.58) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL4770221 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL18324191 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL260258 0.74 CDK8 (0.56) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL21352246 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4
SCHEMBL10247 0.74 CDK8 (0.53) CDK8ROCK1CHEK1DYRK1BMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018217-B2 Phenylimidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2015-04-28 US claimed
US-20150025081-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2015-01-22 US claimed
EP-2318394-B1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2014-01-22 EP claimed
US-20120135987-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-05-31 US claimed
JP-2011524381-A 2011-09-01 JP claimed
WO-2011072695-A1 PHENYLIMIDAZOLE DERIVATIVES COMPRISING AN ETHYNYLENE LINKER AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2011-06-23 WO claimed
EP-2318394-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. Lundbeck A/S (DK) 2011-05-11 EP claimed
US-20100016303-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2010-01-21 US claimed
WO-2009152825-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2009-12-23 WO claimed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
EP-4169575-B1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMA (JP) 2026-01-07 EP disclosed
CN-115667259-B Fused ring compounds for inhibiting H-PGDS 佐藤制药株式会社 2025-06-17 CN disclosed
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
EP-4169575-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS Sato Pharmaceutical Co., Ltd. (JP) 2023-04-26 EP disclosed
US-4163745-A ANTIDIABETIC, HYPOGLYCEMIC PFIZER INC. (US) 1979-08-07 US disclosed
US-4141898-A Imidazo pyridinium quaternary salts as hypoglycemic agents PFIZER INC. (US) 1979-02-27 US disclosed
US-4129567-A IMIDAZOPYRIDINES AND ISOB IDINE PFIZER INC. (US) 1978-12-12 US disclosed
US-4097598-A Quaternary salts as hypoglycemic agents PFIZER INC. (US) 1978-06-27 US disclosed
US-4093616-A PYRROLO(1,2-A)PYRAZINIUM, PYRAZOLO(1,5-A)PYRIDINIUM, 1H-IMIDAZO(2,1-A)ISOQUINOLINIUM, OR IMIDAZO(5,1-A)ISOQUINOLINIUM SALTS PFIZER INC. (US) 1978-06-06 US disclosed
US-4044015-A Imidazopyridinium compounds as hypoglycemic agents PFIZER INC. (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016303-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS PDE10A, PDE5A, PDE3B CDK8 1785/4885ROCK1 522/4885CHEK1 3797/4885
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS HPGDS, PTGS1, PTGIS CDK8 1648/4885ROCK1 948/4885CHEK1 4264/4885
US-20120135987-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS PDE10A, PDE5A, PDE3B CDK8 1785/4885ROCK1 522/4885CHEK1 3797/4885
US-20150025081-A1 NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS PDE10A, PDE5A, PDE3B CDK8 1785/4885ROCK1 522/4885CHEK1 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.